9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

2011 ◽  
Vol 47 ◽  
pp. S595 ◽  
Author(s):  
H. Groen ◽  
A.A. Adjei ◽  
G.K. Dy ◽  
J.A. Ware ◽  
G. Shankar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Pi3 Kinase ◽  
Small Cell Lung

scholarly journals A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 245-250 ◽  
Author(s):  
Julian R. Molina ◽  
Nathan R. Foster ◽  
Thanyanan Reungwetwattana ◽  
Garth D. Nelson ◽  
Andrew V. Grainger ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Phase Ii Trial ◽  
Src Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Extensive Stage

scholarly journals Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

MedChemComm ◽  
2017 ◽  
Vol 8 (10) ◽  
pp. 1914-1918
Author(s):  
Lian-Xiang Luo ◽  
Ying Li ◽  
Yu-Zhen Niu ◽  
Yu-Wei Wang ◽  
Qian-Qian Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Fusion Protein ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Alk Inhibitor

Herein, we reported 5067-0952, a potent ALK inhibitor with pharmacological efficacy in non-small cell lung cancers harboring the ALK fusion oncogene.

The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer

2012 ◽  
Vol 66 (3) ◽  
pp. 221-227 ◽  
Author(s):  
Xueying Yang ◽  
Jing Di ◽  
Yang Zhang ◽  
Suning Zhang ◽  
Jibin Lu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Rho Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Rho Kinase Inhibitor ◽  
Proliferation And Metastasis

scholarly journals Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies

2021 ◽  
pp. e286-e293
Author(s):  
Jennifer W. Carlisle ◽  
R. Donald Harvey
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
New Agents ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

The number of therapeutic options available for patients with advanced non–small-cell lung cancer has been led by deeper understanding of molecular drivers, immune function, and fundamental biology. In this article, we describe the relevant clinical pharmacologic characteristics of three broad classes of existing and investigational treatments, with a focus on mechanisms of action, adverse event profiles, pharmacokinetic and pharmacodynamic properties, and known and predicted resistance pathways. Specifically, within the kinase inhibitor class, agents directed against the RET, MET, and KRAS pathways are reviewed. Additionally, the first antibody-drug conjugates that target HER2 and HER3 are in trials and will ideally be available for patients soon. Finally, proteolysis-targeting chimeras approach pathway inhibition through enzyme degradation rather than target inhibition and are a promising platform for new agents in non–small-cell lung cancer and across cancer types. Each of these classes requires knowledge of clinical pharmacologic principles in development and use to ensure patient care in clinics and trials is optimized and personalized, including dosing and scheduling strategies, potential drug interactions, use in special populations, and monitoring parameters. Ideally, oncologists will continue to have new agents available across the non–small-cell lung cancer treatment spectrum to offer to a patient group that, until relatively recently, had few options.

High Kpnβ1 expression promotes non-small cell lung cancer proliferation and chemoresistance via the PI3-kinase/AKT pathway

2018 ◽  
Vol 51 ◽  
pp. 39-48 ◽  
Author(s):  
Haiying Wang ◽  
Danping Wang ◽  
Chunsun Li ◽  
Xingsong Zhang ◽  
Xiaolin Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Pi3 Kinase ◽  
Akt Pathway ◽  
Small Cell Lung ◽  
Cancer Proliferation
Sign in / Sign up

Export Citation Format

Share Document